NLSP vs. CNTX, LVTX, MYNZ, PHVS, PROC, QLI, TLSA, ATNFW, SXTPW, and ACONW
Should you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Context Therapeutics (CNTX), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), Pharvaris (PHVS), Procaps Group (PROC), Qilian International Holding Group (QLI), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), and Aclarion (ACONW). These companies are all part of the "medical" sector.
NLS Pharmaceutics (NASDAQ:NLSP) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
Context Therapeutics received 4 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 63.16% of users gave Context Therapeutics an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote.
In the previous week, Context Therapeutics had 7 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 9 mentions for Context Therapeutics and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.43 beat Context Therapeutics' score of 1.10 indicating that NLS Pharmaceutics is being referred to more favorably in the media.
14.0% of Context Therapeutics shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 6.7% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
NLS Pharmaceutics has a beta of -0.7, indicating that its stock price is 170% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.
Context Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 301.07%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than NLS Pharmaceutics.
NLS Pharmaceutics' return on equity of 0.00% beat Context Therapeutics' return on equity.
Summary
Context Therapeutics beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks.
Get NLS Pharmaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NLS Pharmaceutics Competitors List
Related Companies and Tools
